Jump to: navigation, search
PBB Protein PLG image.jpg
PDB rendering based on 1b2i.
Symbol(s) PLG; DKFZp779M0222
External IDs OMIM: 173350 MGI97620 Homologene55452
RNA expression pattern

PBB GE PLG 209978 s at tn.png

PBB GE PLG 209977 at tn.png

PBB GE PLG 205871 at tn.png

More reference expression data

Human Mouse
Entrez 5340 18815
Ensembl ENSG00000122194 ENSMUSG00000059481
Uniprot P00747 Q3V1T9
Refseq NM_000301 (mRNA)
NP_000292 (protein)
NM_008877 (mRNA)
NP_032903 (protein)
Location Chr 6: 161.04 - 161.09 Mb Chr 17: 12.22 - 12.26 Mb
Pubmed search [1] [2]

WikiDoc Resources for Plasmin


Most recent articles on Plasmin

Most cited articles on Plasmin

Review articles on Plasmin

Articles on Plasmin in N Eng J Med, Lancet, BMJ


Powerpoint slides on Plasmin

Images of Plasmin

Photos of Plasmin

Podcasts & MP3s on Plasmin

Videos on Plasmin

Evidence Based Medicine

Cochrane Collaboration on Plasmin

Bandolier on Plasmin

TRIP on Plasmin

Clinical Trials

Ongoing Trials on Plasmin at Clinical

Trial results on Plasmin

Clinical Trials on Plasmin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Plasmin

NICE Guidance on Plasmin


FDA on Plasmin

CDC on Plasmin


Books on Plasmin


Plasmin in the news

Be alerted to news on Plasmin

News trends on Plasmin


Blogs on Plasmin


Definitions of Plasmin

Patient Resources / Community

Patient resources on Plasmin

Discussion groups on Plasmin

Patient Handouts on Plasmin

Directions to Hospitals Treating Plasmin

Risk calculators and risk factors for Plasmin

Healthcare Provider Resources

Symptoms of Plasmin

Causes & Risk Factors for Plasmin

Diagnostic studies for Plasmin

Treatment of Plasmin

Continuing Medical Education (CME)

CME Programs on Plasmin


Plasmin en Espanol

Plasmin en Francais


Plasmin in the Marketplace

Patents on Plasmin

Experimental / Informatics

List of terms related to Plasmin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [3]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [4] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.


Plasmin is an important enzyme (EC present in blood that degrades many blood plasma proteins, most notably fibrin clots. The degradation of fibrin is termed fibrinolysis.


It is a serine protease that is released as plasminogen into the circulation and activated by tissue plasminogen activator (tPA), urokinase plasminogen activator (uPA), thrombin, fibrin and factor XII (Hageman factor). It is inactived by alpha 2-antiplasmin, a serine protease inhibitor (serpin).

Apart from fibrinolysis, plasmin proteolyses proteins in various other systems: it activates collagenases, some mediators of the complement system and weakens the wall of the Graafian follicle (leading to ovulation). It cleaves fibrin, fibronectin, thrombospondin, laminin and von Willebrand factor.

Fibrinolysis (simplified). Blue arrows denote stimulation, and red arrows inhibition.


Deficiency in plasmin may lead to thrombosis, as clots are not degraded adequately.

Further reading

  • Anglés-Cano E, Rojas G (2003). "Apolipoprotein(a): structure-function relationship at the lysine-binding site and plasminogen activator cleavage site.". Biol. Chem. 383 (1): 93–9. PMID 11928826. 
  • Ranson M, Andronicos NM (2004). "Plasminogen binding and cancer: promises and pitfalls.". Front. Biosci. 8: s294–304. PMID 12700073. 

External links

Cost Effectiveness of Plasmin

| group5 = Clinical Trials Involving Plasmin | list5 = Ongoing Trials on Plasmin at Clinical Trials.govTrial results on PlasminClinical Trials on Plasmin at Google

| group6 = Guidelines / Policies / Government Resources (FDA/CDC) Regarding Plasmin | list6 = US National Guidelines Clearinghouse on PlasminNICE Guidance on PlasminNHS PRODIGY GuidanceFDA on PlasminCDC on Plasmin

| group7 = Textbook Information on Plasmin | list7 = Books and Textbook Information on Plasmin

| group8 = Pharmacology Resources on Plasmin | list8 = AND (Dose)}} Dosing of PlasminAND (drug interactions)}} Drug interactions with PlasminAND (side effects)}} Side effects of PlasminAND (Allergy)}} Allergic reactions to PlasminAND (overdose)}} Overdose information on PlasminAND (carcinogenicity)}} Carcinogenicity information on PlasminAND (pregnancy)}} Plasmin in pregnancyAND (pharmacokinetics)}} Pharmacokinetics of Plasmin

| group9 = Genetics, Pharmacogenomics, and Proteinomics of Plasmin | list9 = AND (pharmacogenomics)}} Genetics of PlasminAND (pharmacogenomics)}} Pharmacogenomics of PlasminAND (proteomics)}} Proteomics of Plasmin

| group10 = Newstories on Plasmin | list10 = Plasmin in the newsBe alerted to news on PlasminNews trends on Plasmin</small>

| group11 = Commentary on Plasmin | list11 = Blogs on Plasmin

| group12 = Patient Resources on Plasmin | list12 = Patient resources on PlasminDiscussion groups on PlasminPatient Handouts on PlasminDirections to Hospitals Treating PlasminRisk calculators and risk factors for Plasmin

| group13 = Healthcare Provider Resources on Plasmin | list13 = Symptoms of PlasminCauses & Risk Factors for PlasminDiagnostic studies for PlasminTreatment of Plasmin

| group14 = Continuing Medical Education (CME) Programs on Plasmin | list14 = CME Programs on Plasmin

| group15 = International Resources on Plasmin | list15 = Plasmin en EspanolPlasmin en Francais

| group16 = Business Resources on Plasmin | list16 = Plasmin in the MarketplacePatents on Plasmin

| group17 = Informatics Resources on Plasmin | list17 = List of terms related to Plasmin

}}de:Plasmin it:Plasmina